Impact of 2 days of staging at 2500–4300 m on sleep quality and quantity following subsequent exposure to 4300 m

Abstract The impact of 2 days of staging at 2500–4300 m on sleep quality and quantity following subsequent exposure to 4300 m was determined. Forty‐eight unacclimatized men and women were randomly assigned to stage for 2 days at one of four altitudes (2500, 3000, 3500, or 4300 m) prior to assessment on the summit of Pikes Peak (4300 m) for 2 days. Volunteers slept for one night at sea level (SL), two nights at respective staging altitudes, and two nights at Pikes Peak. Each wore a pulse oximeter to measure sleep arterial oxygen saturation (sSpO2, %) and number of desaturations (DeSHr, events/hr) and a wrist motion detector to estimate sleep awakenings (Awak, awakes/hr) and sleep efficiency (Eff, %). Acute mountain sickness (AMS) was assessed using the Environmental Symptoms Questionnaire and daytime SpO2 was assessed after AMS measurements. The mean of all variables for both staging days (STG) and Pikes Peak days (PP) was calculated. The sSpO2 and daytime SpO2 decreased (p 0.05) between groups. At PP, the sSpO2, DeSHr, Awak, and Eff were similar among all groups but the 2500 m group had greater AMS symptoms (p